Modeling "psychosis" in Vitro by Inducing Disordered Neuronal Network Activity in Cortical Brain Slices

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2009 Feb 26

PMID 19241062

Citations 20

Authors

George K Aghajanian

Affiliations

Soon will be listed here.

Abstract

Introduction: Dysregulation of neuronal networks has been suggested to underlie the cognitive and perceptual abnormalities observed schizophrenia.

Discussions: An in vitro model of psychosis is proposed based on the two different approaches to cause aberrant network activity in layer V pyramidal cells of prefrontal brain slices: (1) psychedelic hallucinogens such as lysergic acid diethylamide and (2) minimal GABA(A) receptor antagonism, modeling the GABA interneuron deficit in schizophrenia. A test of this model would be to determine if drugs that normalize aberrant networks in brain slices have efficacy in the treatment of schizophrenia. Selective agonists of glutamate mGlu2/3 metabotropic receptors, which are highly effective in suppressing aberrant network activity in slices, are the most advanced toward reaching that clinical endpoint. In accord with the model, a recent phase II clinical trial shows that an mGlu2/3 receptor agonist is equivalent in efficacy to a standard antipsychotic drug for both negative and positive symptoms in schizophrenic patients, but without the usual side effects. D1/5 dopamine receptor agonists are also effective in normalizing aberrant network activity induced by both hallucinogens and minimal GABA(A) antagonism; clinical efficacy remains to be determined. A general model of network regulation is presented, involving astrocytes, GABA interneurons, and glutamatergic pyramidal cells, revealing a wide range of potential sites hitherto not considered as therapeutic targets.

Citing Articles

On the functions of astrocyte-mediated neuronal slow inward currents.

Pal B Neural Regen Res. 2024; 19(12):2602-2612.

PMID: 38595279 PMC: 11168512. DOI: 10.4103/NRR.NRR-D-23-01723.

Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.

Marek G, Salek A J Pharmacol Exp Ther. 2020; 374(1):200-210.

PMID: 32265323 PMC: 7318837. DOI: 10.1124/jpet.119.264069.

Alterations of Astrocytes in the Context of Schizophrenic Dementia.

Tarasov V, Svistunov A, Chubarev V, Sologova S, Mukhortova P, Levushkin D Front Pharmacol. 2020; 10:1612.

PMID: 32116664 PMC: 7020441. DOI: 10.3389/fphar.2019.01612.

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Carhart-Harris R, Friston K Pharmacol Rev. 2019; 71(3):316-344.

PMID: 31221820 PMC: 6588209. DOI: 10.1124/pr.118.017160.

β-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate.

Marek G, Ramos B Front Pharmacol. 2018; 9:89.

PMID: 29472863 PMC: 5809958. DOI: 10.3389/fphar.2018.00089.

References

Seamans J, Durstewitz D, Christie B, Stevens C, Sejnowski T . Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A. 2001; 98(1):301-6. PMC: 14585. DOI: 10.1073/pnas.98.1.301. View

Marek G, Wright R, Schoepp D, Monn J, Aghajanian G . Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 1999; 292(1):76-87. View

Moghaddam B, Adams B, Verma A, Daly D . Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997; 17(8):2921-7. PMC: 6573099. View

Moghaddam B, Adams B . Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281(5381):1349-52. DOI: 10.1126/science.281.5381.1349. View

Guidotti A, Auta J, Davis J, Dong E, Grayson D, Veldic M . GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl). 2005; 180(2):191-205. DOI: 10.1007/s00213-005-2212-8. View

Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

George M, Molnar C, Grenesko E, Anderson B, Mu Q, Johnson K . A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res. 2007; 93(1-3):42-50. DOI: 10.1016/j.schres.2007.03.011. View

Beierlein M, Fall C, Rinzel J, Yuste R . Thalamocortical bursts trigger recurrent activity in neocortical networks: layer 4 as a frequency-dependent gate. J Neurosci. 2002; 22(22):9885-94. PMC: 6757840. View

Lambe E, Aghajanian G . Hypocretin (orexin) induces calcium transients in single spines postsynaptic to identified thalamocortical boutons in prefrontal slice. Neuron. 2003; 40(1):139-50. DOI: 10.1016/s0896-6273(03)00598-1. View

10.

SCHOTTE A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A . Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124(1-2):57-73. DOI: 10.1007/BF02245606. View

11.

Aghajanian G, Marek G . Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 1999; 825(1-2):161-71. DOI: 10.1016/s0006-8993(99)01224-x. View

12.

Danos P, Baumann B, Bernstein H, Franz M, Stauch R, Northoff G . Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res. 1998; 82(1):1-10. DOI: 10.1016/s0925-4927(97)00071-1. View

13.

Zahrt J, Taylor J, Mathew R, Arnsten A . Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997; 17(21):8528-35. PMC: 6573725. View

14.

Aghajanian G, Marek G . Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 1997; 36(4-5):589-99. DOI: 10.1016/s0028-3908(97)00051-8. View

15.

Lambe E, Aghajanian G . Prefrontal cortical network activity: Opposite effects of psychedelic hallucinogens and D1/D5 dopamine receptor activation. Neuroscience. 2007; 145(3):900-10. PMC: 1894690. DOI: 10.1016/j.neuroscience.2006.12.048. View

16.

Merchant R, Bullock M, Carmack C, Shah A, Wilner K, Ko G . A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci. 2000; 890:42-50. DOI: 10.1111/j.1749-6632.1999.tb07979.x. View

17.

Conn P, Pin J . Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. DOI: 10.1146/annurev.pharmtox.37.1.205. View

18.

Lang D, Khorram B, Goghari V, Kopala L, Vandorpe R, Rui Q . Reduced anterior internal capsule and thalamic volumes in first-episode psychosis. Schizophr Res. 2006; 87(1-3):89-99. DOI: 10.1016/j.schres.2006.05.002. View

19.

Stark A, Uylings H, Sanz-Arigita E, Pakkenberg B . Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry. 2004; 161(5):882-8. DOI: 10.1176/appi.ajp.161.5.882. View

20.

Higgins G, Ballard T, Enderlin M, Haman M, Kemp J . Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl). 2005; 179(1):85-98. DOI: 10.1007/s00213-005-2203-9. View